TY - JOUR
T1 - Cardiomyopathies in Noonan syndrome and the other RASopathies
AU - Gelb, Bruce D.
AU - Roberts, Amy E.
AU - Tartaglia, Marco
N1 - Publisher Copyright:
© 2015 Elsevier Ireland Ltd.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Noonan syndrome and related disorders (Noonan syndrome with multiple lentigines, Costello syndrome, cardiofaciocutaneous syndrome, Noonan syndrome with loose anagen hair, and other related traits) are autosomal dominant traits. Mutations causing these disorders alter proteins relevant for signaling through RAS. Thus, these traits are now collectively called the RASopathies. While the RASopathies have pleiomorphic features, this review will focus on the hypertrophic cardiomyopathy observed in varying percentages of all of these traits. In addition, inherited abnormalities in one pathway gene, RAF1, cause pediatric-onset dilated cardiomyopathy. The pathogeneses for the RASopathy-associated cardiomyopathies are being elucidated, principally using animal models, leading to genotype-specific insights into how signal transduction is perturbed. Based on those findings, small molecule therapies seem possible for RASopathy-associated cardiomyopathies.
AB - Noonan syndrome and related disorders (Noonan syndrome with multiple lentigines, Costello syndrome, cardiofaciocutaneous syndrome, Noonan syndrome with loose anagen hair, and other related traits) are autosomal dominant traits. Mutations causing these disorders alter proteins relevant for signaling through RAS. Thus, these traits are now collectively called the RASopathies. While the RASopathies have pleiomorphic features, this review will focus on the hypertrophic cardiomyopathy observed in varying percentages of all of these traits. In addition, inherited abnormalities in one pathway gene, RAF1, cause pediatric-onset dilated cardiomyopathy. The pathogeneses for the RASopathy-associated cardiomyopathies are being elucidated, principally using animal models, leading to genotype-specific insights into how signal transduction is perturbed. Based on those findings, small molecule therapies seem possible for RASopathy-associated cardiomyopathies.
KW - Dilated cardiomyopathy
KW - Hypertrophic cardiomyopathy
KW - RAS/MAP kinase signal transduction
KW - RASopathies
UR - http://www.scopus.com/inward/record.url?scp=84938555313&partnerID=8YFLogxK
U2 - 10.1016/j.ppedcard.2015.01.002
DO - 10.1016/j.ppedcard.2015.01.002
M3 - Review article
AN - SCOPUS:84938555313
SN - 1058-9813
VL - 39
SP - 13
EP - 19
JO - Progress in Pediatric Cardiology
JF - Progress in Pediatric Cardiology
IS - 1
ER -